SVCM
FOLD

Saturn V Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Saturn V Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-713,536
Closed -$7.08M – 28
2024
Q2 		$7.08M Sell
713,536
-184,845
-21% -$1.9M 2.67% 16
2024
Q1 		$10.6M Buy
898,381
+698,408
+349% +$8.93M 4.24% 11
2023
Q4 		$2.84M Buy
+199,973
New +$2.27M 1.09% 19
2023
Q2 		– Sell
-258,288
Closed -$2.86M – 22
2023
Q1 		$2.86M Sell
258,288
-307,891
-54% -$3.8M 2.14% 14
2022
Q4 		$4.89M Buy
+566,179
New +$6.37M 4.06% 15

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Saturn V Capital Management's FOLD Position: Q3 2024 in Review

Saturn V Capital Management sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 713,536 shares — an estimated $7.08M sold.

Saturn V Capital Management first reported a position in FOLD in Q4 2022 and held it in 5 quarters. The position peaked at $10.6M in Q1 2024. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • Saturn V Capital Management reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 713,536 Amicus Therapeutics shares in Q3 2024, an estimated $7.08M.
  • Saturn V Capital Management first reported a position in Amicus Therapeutics in Q4 2022 and held it in 5 quarters.
  • Saturn V Capital Management's Amicus Therapeutics position peaked at $10.6M in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Saturn V Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.